- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Ernexa Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.02. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering | 134 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) ("Ernexa" or the "Company"), an industry innovator developing novel cell therapies for the treatment of... ► Artikel lesen | |
| 05.02. | Ernexa Therapeutics Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 04.02. | Ernexa Therapeutics Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| ERNEXA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.02. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA | 1 | GlobeNewswire (USA) | ||
| 27.01. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program | 1 | GlobeNewswire (USA) | ||
| 06.01. | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 11.12.25 | Ernexa Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12.25 | Ernexa Therapeutics: Aktie fällt trotz positiver Studiendaten | 2 | Investing.com Deutsch | ||
| 08.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 03.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 02.12.25 | Ernexa Therapeutics appoints oncologist Dr. Winer to advisory board | 1 | Investing.com | ||
| 02.12.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG | 1 | GlobeNewswire (USA) | ||
| 11.11.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics to Present at Oxford Global's Cell 2025 | 2 | GlobeNewswire (USA) | ||
| 10.11.25 | Eterna Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 10.11.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials | 148 | GlobeNewswire (Europe) | The Company's operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program... ► Artikel lesen | |
| 07.11.25 | Ernexa Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Ernexa Therapeutics Inc.: Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform | 1 | GlobeNewswire (USA) | ||
| 29.10.25 | Cellipont Bioservices and Ernexa Therapeutics Enter Cell Therapy Manufacturing Partnership to Advance ERNA-101 Toward Clinical Trials in Ovarian Cancer | 183 | PR Newswire | THE WOODLANDS, Texas, and CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization... ► Artikel lesen | |
| 29.10.25 | Ernexa Therapeutics stock soars after Cellipont manufacturing deal | 3 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DISC MEDICINE | 56,12 | -21,67 % | Disc Medicine Inc: Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP | FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use... ► Artikel lesen | |
| ARCELLX | 68,50 | -0,22 % | Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study | ||
| AVIDITY BIOSCIENCES | 72,88 | -0,05 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| QIAGEN | 42,905 | +0,13 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der... ► Artikel lesen | |
| UPSTREAM BIO | 8,740 | -31,72 % | Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma | - Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing - - Verekitug also delivered... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 60,78 | -3,91 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| ZENAS BIOPHARMA | 26,520 | +1,57 % | Zenas BioPharma's MS drug shows 95% reduction in brain lesions | ||
| APOGEE THERAPEUTICS | 67,74 | -2,27 % | Here is Why Apogee Therapeutics (APGE) Appears Attractive | ||
| PRAXIS PRECISION MEDICINES | 317,31 | -4,69 % | Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX) | ||
| RECURSION PHARMACEUTICALS | 3,495 | -2,37 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,930 | +3,71 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| ERASCA | 12,020 | -2,36 % | Stifel bestätigt Kaufempfehlung für Erasca mit Kursziel von 10 US-Dollar | ||
| MINERALYS THERAPEUTICS | 27,600 | -0,93 % | Mineralys Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| TANGO THERAPEUTICS | 12,900 | +1,82 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| IMMUNOME | 22,160 | -1,25 % | H.C. Wainwright initiates coverage on Immunome stock with Buy rating |
ERNEXA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,327 Euro und damit -10,20 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERNEXA THERAPEUTICS INC finden Sie auf Wallstreet Online.